Catalent (NYSE:CTLT) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS


Share on StockTwits

Catalent (NYSE:CTLT) posted its quarterly earnings results on Tuesday. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.08, MarketWatch Earnings reports. Catalent had a return on equity of 14.20% and a net margin of 9.25%. The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $994.28 million. During the same quarter in the prior year, the business earned $0.50 EPS. The firm’s revenue for the quarter was up 38.5% on a year-over-year basis. Catalent updated its FY 2021 guidance to 2.780-2.970 EPS.

Shares of NYSE CTLT opened at $103.50 on Wednesday. The stock has a market capitalization of $17.62 billion, a PE ratio of 65.92, a P/E/G ratio of 2.68 and a beta of 1.50. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.56 and a quick ratio of 2.14. The business has a fifty day moving average price of $108.50 and a two-hundred day moving average price of $106.45. Catalent has a fifty-two week low of $65.00 and a fifty-two week high of $127.68.

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada increased their price objective on shares of Catalent from $125.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, February 3rd. UBS Group raised their price objective on shares of Catalent from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, February 3rd. Morgan Stanley upped their target price on Catalent from $115.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, February 3rd. Argus increased their target price on Catalent from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, March 2nd. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. boosted their price target on Catalent from $110.00 to $130.00 and gave the company an “overweight” rating in a research note on Friday, January 8th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Catalent has a consensus rating of “Buy” and an average price target of $125.11.

In related news, CEO John R. Chiminski sold 42,220 shares of the stock in a transaction that occurred on Thursday, March 18th. The shares were sold at an average price of $105.16, for a total transaction of $4,439,855.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Kay A. Schmidt sold 1,400 shares of Catalent stock in a transaction that occurred on Monday, March 22nd. The shares were sold at an average price of $105.77, for a total transaction of $148,078.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 74,871 shares of company stock valued at $7,997,007. Corporate insiders own 1.00% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Story: How are the companies in the S&P 500 selected?

Earnings History for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.